Showing posts with label ellis martin. Show all posts
Showing posts with label ellis martin. Show all posts

Monday, October 17, 2011

The Ellis Martin Report: Interview with International Stem Cell Corporation's Founder and Co-Chairman Kenneth Aldrich


Brief Overview:
Lifeline Skin Care – LLSC
Remodeled marketing and structure of subsidiary to reach broader base of users and use multiple distribution channels including International distribution network, spas and resorts plus increased product supply.

Lifeline Cell tech - LLCT
Recently seeing results from distributorships expansion throughout several countries in Asia. 

International Stem Cell Corporation - ISCO
Started first animal trials with a class of neurons developed with our parthenogenic stem cells, proprietary only to ISCO, to develop what we think has great promise for treating Parkinson’s disease and possibly other diseases.  

Tuesday, September 6, 2011

Video: The Promising Cells Presented by International Stem Cell Corporation

Ken Aldrich of International Stem Cell Corporation (ISCO.OB) on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body...as well as other applications. Mr. Aldrich also discusses neurological applications focusing on reversing Parkinson's disease.

This corporate video was produced by Big Sky Productions Inc. (BGSI.OB).
Executive Producer: Ellis Martin
Producer and Creative Director, Narrator, Editor: Bob Lange


Monday, August 29, 2011

Part 5: The Ellis Martin Report with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)

In this interview, Ellis Martin speaks with Kenneth Aldrich of International Stem Cell Corporation (ISCO.OB) about continuing research and revenue generated by Lifeline Stem Cell technology, including Lifeline Skin Care Creams. Is International Stem Cell working on a cure for melanoma or cancer? Not directly, but the company believes that their technology is being used by their client companies doing research for these cures. Listen to the interview for full details. http://www.ellimartinreport.com  http://www.intlstemcell.com  contact:martinreports@gmail.com

International Stem Cell Corp is paid sponsor of The Ellis Martin Report. Forward looking statements may have been made in this interview.


Monday, August 22, 2011

Part 4: The Ellis Martin Report with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)

Ellis Martin of The Ellis Martin Report interviews Ken Aldrich of International Stem Cell Corporation (ISCO.OB) on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body...as well as other applications. Mr. Aldrich also discusses neurological applications focusing on reversing Parkinson's disease. http://www.ellismartinreport.com Contact: martinreports@gmail.com. International Stem Cell is a paid sponsor of The Ellis Martin Report



Monday, August 8, 2011

The Ellis Martin Report: Interview with Ken Aldrich of International Stem Cell Corp.



Please click on the arrow above to listen to the complete interview.

"Ken Aldrich of International Stem Cell Corp (ISCO.OB) on the Present and Future of Stem Cell Research and Applications"

The Ellis Martin Report: International Stem Cell Corporation trades under the symbol ISCO.OB on the Over the Counter Bulletin Board and is based in Carlsbad, California where I have the pleasure of interviewing Executive Chairman, Kenneth Aldrich. International Stem Cell has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISCO a unique leadership role in the field of regenerative cell therapy. Additionally, Lifeline Cell Technology, a wholly-owned subsidiary of International Stem Cell Corporation (ISCO), develops, manufactures and markets high-quality human primary cells, stem cells, media and reagents for sale to pharmaceutical, academic and government scientists. The company’s management pioneered the development of the normal human cell culture market through the creation of Clonetics® Corporation in the 1980s and has over 20 years combined experience in research, development, manufacturing, quality control, marketing and sales of human cell culture products. Lifeline’s products are distributed in the United States and Europe. Ken Aldrich, welcome to the program.

For the complete text version of this broadcast: http://www.ellismartinreport.com/node/148



Sunday, July 31, 2011

International Stem Cell Corporation Chairman Ken Aldrich Interviewed by Ellis Martin

"The Ellis Martin Report features interviews with exciting, potentially undervalued small and mid-cap publicly traded companies, showcased to an audience of potential retail investors during market hours throughout the United States."


Ellis Martin with Ken Aldrich of International Stem Cell Corporation (ISCO.OB)
Listen to full interview here: http://www.youtube.com/watch?v=WUyFYSGhNjc&feature=share or you can read a Transcript of the conversation here: http://www.ellismartinreport.com/node/148
(Scroll down to view this week's Radio Schedule for ISCO.)

“International Stem Cell Corporation trades under the symbol ISCO.OB on the Over the Counter Bulletin Board and is based in Carlsbad, California where Ellis Martin had the pleasure of interviewing Executive Chairman Kenneth Aldrich.

International Stem Cell has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISCO a unique leadership role in the field of regenerative cell therapy. Additionally, Lifeline Cell Technology, a wholly-owned subsidiary of International Stem Cell Corporation (ISCO) develops, manufactures and markets high-quality human primary cells, stem cells, media and reagents for sale to pharmaceutical, academic and government scientists.

The company's management pioneered the development of the normal human cell culture market through the creation of Clonetics® Corporation in the 1980s and has over 20 years combined experience in research, development, manufacturing, quality control, marketing and sales of human cell culture products. Lifeline Cell Tech’s products are distributed in the United States and Europe.”



Monday, August 1st at 1:00pm

WVNJ-NY/NJ - AM1160      

Tuesday, August 2nd at 10:00am
KCEO - AM1000    
San Diego/Orange County/LA Beach Cities

Tuesday, August 2nd at 9:30am and Friday, August 5th at 3:30pm
WSBR-AM - 740 FM 95.5  
Boca Raton, West Palm Beach, Ft. Lauderdale, Miami

Mondays and Wednesdays at 1:00pm
WBNM-AM 1120
Boston and New England through: WESO AM 970 and WCRN AM 830

Ellis Martin Report

International Stem Cell Corporation

International Stem Cell Corporation is a paid sponsor of The Ellis Martin Report

Click here to listen to the entire interview: http://www.youtube.com/watch?v=WUyFYSGhNjc&feature=share